You just read:

MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy

News provided by

MabVax Therapeutics Holdings, Inc.

Dec 20, 2017, 06:05 EST